Table 1 Mesenchymal stem cells (MSCs) collected from bone marrow (BM), umbilical cord (UC), Wharton jelly (WJ), adipose tissue (ADSCs), dental pulp (DP) or manufactured biological preparations of MSCs are administered to COVID-19 patients
From: Exosomes contribution in COVID-19 patients’ treatment
Clinical trial status | Study objective | MSC origin used/mode of administration | Dose or total administered cells | Phase | Locations |
|---|---|---|---|---|---|
Completed | Safety and efficacy Pneumonia Cytokine syndrome | UC-MSC/I.V BM-MSC/I.V ADSC/I.V | 3 × 106/kg or 5 × 107–4 × 108 cells | 1/2 | USA, Japan, Turkey, China, Pakistan, Indonesia |
Safety and efficacy Pneumonia | Exosomes inhalation | 0.5–2 × 1010 nanoparticles | 1/2 | Russian, China | |
Recruiting |  | BM-MSC/I.V WJ-MSC/I.V UC-MSC/I.V ADSC/I.V Biological MSC/I.V DP-MSC/I.V Cryopreserved placenta derived-MSC/I.V Biological preparations of MSCs | 1,5 × 106–9 × 106/kg or 1 × 108–7.5 × 108 cells | 1/2 | Spain, USA, China, Jordan, Mexico, Indonesia, Ukraine, Colombia, UK, Canada, Pakistan, Australia, Turkey |
Cytokine syndrome | Secretome/intramuscular | 1CC/12 h × 3 days | 2 | Indonesia | |
Pneumonia | BM-MSC + exosomes/I.V | 2 × 108 + Exosome dose (NA) | 2/3 | Iran | |
Not yet recruiting | Pneumonia Efficacy | UC-, BM-, ADSCs-, DP-MSCs, biological preparations/I.V | 5 × 105–2 × 107/Kg or 8 × 107–6 × 108 cells | 1/2 | Brazil, China, USA, Germany |
Viral inflammation Pneumonia | MSCs derived exosomes (ARDOXO)/ I.V UCB educator and MSCs secretome/ IV | 2–8 × 109/ml 1 × 106/Kg or conditioned media | 1/2 | USA | |
Active not recruiting | Pneumonia Safety and efficacy | WJ-, UCB-MSCs, ADSCs/ I.V | 4 × 106/Kg or 8 × 107–8 × 108 cells | 1/2 | Mexico, USA, China, Spain |